In Oncology, Antibody-Drug Conjugates Are a Hot Ticket
Major drug companies have been snatching up biotech companies that developing antibody-drug conjugates (ADCs) targeting a variety of cancers.
Investment in Vaccine Development is Low. How Can That Be Fixed?
The Biotechnology Innovation Organization has some suggestions, including "platform designation" by FDA and changes at the CDC.
Dermatology’s Embrace of JAK inhibitors
The FDA has approved six with dermatologic indications and more are in late-stage trials.
Medicare Advantage, Racing Along, Hits Some Speed Bumps
Enrollment has soared, but a relatively modest 2025 rate increase and changes to the Star rating system may lead plans to cut back on with their benefit offerings.
A New Kid on the Block of Therapy for Acute Myeloid Leukemia
Crenolanib may have advantages over other therapies targeting acute myeloid leukemia with FLT3 gene mutations.
As Data Pile Up, Some Healthcare Organizations Turn To ‘Lakehouses’
Healthcare organizations generate and store vast amounts of data but they often have to choose between speed and structure. Data "lakehouses" may be the answer.
